Table 1

Summary of the SUSTAIN results9 10 16 20–26

Trial (n)Background regimen†Doses and comparatorsBody weight change from baseline (kg)Patients with weight loss of>5% (%)
SUSTAIN 1 (n=388)13Diet and ExerciseSC semaglutide 0.5 mg–3.73*37*
SC semaglutide 1.0 mg–4.53*45*
Placebo–0.987
SUSTAIN 2 (n=1231)8Metformin, pioglitazone, rosiglitazoneSC semaglutide 0.5 mg–4.3*46*
SC semaglutide 1.0 mg–6.1*62*
Sitagliptin 100 mg–1.918
SUSTAIN 3 (n=809)9Metformin, Sulfonylurea, ThiazolidinedioneSC semaglutide 1.0 mg–5.6*52*
Exenatide ER 2 mg–1.917
SUSTAIN 4 (n=1089)15Metformin, SulfonylureaSC semaglutide 0.5 mg–3.47*37*
SC semaglutide 1.0 mg–5.17*51*
Insulin glargine1.155
SUSTAIN 5 (n=397)12Metformin, Basal insulinSC semaglutide 0.5 mg–3.7*42*
SC semaglutide 1.0 mg–6.4*66*
Placebo–1.411
SUSTAIN 6 (n=3297)110–2 antihyperglycemic agentsSC semaglutide 0.5 mg–3.6*NR
SC semaglutide 1.0 mg–4.9*
Placebo 1.0 mg–0.7
Placebo 0.5 mg–0.5
SUSTAIN 7 (n=1201)16MetforminSC semaglutide 0.5 mg–4.6*44*
Dulaglutide 0.75 mg–2.323
SC semaglutide 1.0 mg–2.3*63*
Dulaglutide 1.5 mg–1.130
SUSTAIN 8 (n=788)17MetforminSC semaglutide 1.0 mg–5.3*53
Canagliflozin 300 mg–4.247
SUSTAIN 9 (n=302)14Metformin, Sulfonylurea, SGLT-2 inhibitorSC semaglutide 1.0 mg–4.7*50*
Placebo–0.98
SUSTAIN 10 (n=577)18Metformin, SGLT-2 inhibitorSC semaglutide 1.0 mg–5.8*56*
Liraglutide 1.2 mg–1.918
  • *P<0.05 indicating the the superiority of semaglutide vs the respective comparator.

  • †Alone or in combination with one another.

  • ER, extended release; NR, not recorded; SC, subcutaneous; SGLT-2, sodium glucose cotransporter 2; SUSTAIN, Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes.